Celemics

Celemics Net Debt

The Net Debt of Celemics (331920.KQ) as of Oct 30, 2026 is -9.86 B KRW. In the previous year, Net Debt was -10.24 B KRW — a change of -3.69% (higher).

Net Debt

-9.86 BKRW

YoY

-3.69%

Last updated:

Net Debt of Celemics is 2024 -9.86 B KRW. Net Debt of Celemics was 2023 -10.24 B KRW. It decreases by -3.69% higher compared to the previous year.

The Celemics Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
7.61 B KRW
Jan 1, 2018
10.81 B KRW
Jan 1, 2019
-1.17 B KRW
Jan 1, 2020
-26.00 B KRW
Jan 1, 2021
-19.79 B KRW
Jan 1, 2022
-12.02 B KRW
Jan 1, 2023
-10.24 B KRW
Jan 1, 2024
-9.86 B KRW
The Celemics Net Debt history
YEARNet DebtYoY
-9.86 BKRW-3.69%
-10.24 BKRW-14.82%
-12.02 BKRW-39.25%
-19.79 BKRW-23.89%
-26.00 BKRW+2,121.25%
-1.17 BKRW-110.83%
10.81 BKRW+42.02%
7.61 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Net Debt of Celemics is -9.86 B KRW in 2024.

Net Debt of Celemics changed from -10.24 B KRW to -9.86 B KRW, representing a -3.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Celemics since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Celemics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celemics

All Key Metrics — Celemics